Pharmacotherapy for Weight Management in the VHA
Tóm tắt
Từ khóa
Tài liệu tham khảo
Department of Veterans Affairs and Department of Defense. VA/DoD Clinical Practice Guideline for Screening and Management of Overweight and Obesity, version 2.0, 2014. http://www.healthquality.va.gov/guidelines/CD/obesity/CPGManagementOfOverweightAndObesityFINAL041315.pdf Accessed July 17, 2016.
Kahwati L, Trang XL, Jones KR, Kinsinger LS. RE-AIM evaluation of the Veterans Health Administration’s MOVE! Weight Management Program. Transl Behav Med. 2011;1:551–60.
U.S. Department of Veterans Affairs MOVE! Weight Management Program. Available at: http://www.move.va.gov/ . Accessed July 22, 2016.
Data from the Pharmacy Benefits Management Services (PBM) prescription database (Hines, IL). July 21, 2016.
Bessesen DH, McCormick E, Saxon DR, et al. Patterns of prescribing of weight loss medications in a large cohort of adults. LB-OR02-05 Presented at the ENDO2016, The Endocrine Society Annual Meeting, Boston, MA, April 3, 2016. Available at: https://endo.confex.com/endo/2016endo/webprogram/Paper28282.html Accessed July 21, 2016.
Hampp C, Kang EM, Borders-Hemphill V. Use of prescription antiobesity drugs in the United States. Pharmacotherapy. 2013;33(12):1299–307.
Block JP, Choudhry NK, Carpenter DP, et al. Time series analyses of the effect of FDA communications on use of prescription weight loss medications. Obesity. 2014;22(3):943–9.
Pillitteri JL, Shiffma S, Rohay JM, Harkins AM, Burton SL, Wadden TA. Use of dietary supplements for weight loss in the United States: results of a national survey. Obesity. 2008;16:790–6.
Geller AI, Shehab N, Weidle NJ, et al. Emergency department visits for adverse events related to dietary supplements. N Engl J Med. 2015;373:1531–40.
Yanovski SZ, Yanovski JA. Long-term drug treatment for obesity: a systematic and clinical review. JAMA. 2014;31(1):74–86.
Ollendorf DA, Cameron CG, Pearson SD. Effectiveness and value of treatment options for obesity—a report for the California technology assessment forum. JAMA Intern Med. 2016;176(2):247–8.
Garvey WT, Mechanick JI, Brett EM, Garber AJ, Hurley DL, Jastreboff AM, Nadolsky K, Pessah-Pollack R, Plodkowski R; Reviewers of the AACE/ACE Obesity Clinical Practice Guidelines. American Association of Clinical Endocrinologists and American College of Endocrinology Clinical Practice Guidelines for Comprehensive Medical Care of Patients with Obesity. Endocrine Pract. In Press, 2016. Epub May 24, 2016. doi: 10.4158/EP161365.GL .
Apovian CM, Aronne LJ, Bessesen DH, et al. Pharmacologic management of obesity: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2015;100:342–62.
Jensen MD, Ryan DH, Apovian CM, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. J Am Coll Cardiol. 2014;63:2985–3023.
Smith SR, Weissman NJ, Anderson CM, et al. Multicenter, placebo-controlled trial of lorcaserin for weight management. N Engl J Med. 2010;363:245–56.
O’Neil PM, Smith SR, Weissman NJ, et al. Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study. Obesity. 2012;20:1426–36.
Fidler MC, Sanchez M, Raether B, et al. A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial. J Clin Endocrinol Metab. 2011;96:3067–77.
Allison DB, Gadde KM, Garvey WT, et al. Controlled-release phentermine/topiramate in severely obese adults: a randomized control trial (EQUIP). Obesity. 2011;20:330–42.
Gadde KM, Allison DB, Ryan DH, et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomized, placebo-controlled, phase 3 trial. Lancet. 2011;377:1341–52.
Pi-Sunyer X, Astrup A, Fujioka K, Greenway F, Halpern A, et al. Randomized, controlled trial of 3.0 mg of Liraglutide in weight management. N Engl J Med. 2015;373:11–22.
Astrup A, Rossner S, Van Gaal L, et al. Effects of liraglutide in the treatment of obesity: a randomized, double-blind, placebo-controlled study. Lancet. 2009;374:1606–16.
Wadden TA, Hollander P, Klein S, et al. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study. Int J Obes. 2013;37:1443–51.
Yanovski SZ, Yanovski JA. Naltrexone extended-release plus bupropion extended-release for treatment of obesity. JAMA. 2015;313(12):1213–4.
Greenway FL, Fujioka K, Plodkowski RA, et al. COR-I Study Group. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I). Lancet. 2010;376(9741):595–605.
Apovian CM, Aronne L, Rubino D, et al. COR-II Study Group. A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II). Obesity (Silver Spring). 2013;21(5):935–43.
Wadden TA, Foreyt JP, Foster GD, et al. Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial. Obesity (Silver Spring). 2011;19(1):110–20.
Hollander P, Gupta AK, Plodkowski R, et al. COR-Diabetes Study Group. Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes. Diabetes Care. 2013;36(12):4022–9.
Khera R, Murad MH, Chandar AK, et al. Association of pharmacological treatments for obesity with weight loss and adverse events: a systematic review and meta-analysis. JAMA. 2016;315:2424–34.